Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer

Wei Luo, Adam R. Karpf, Kristin K. Deeb, Josephia R. Muindi, Carl D. Morrison, Candace S. Johnson, Donald L. Trump

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Calcitriol, a regulator of calcium homeostasis with antitumor properties, is degraded by the product of the CYP24A1 gene, which is downregulated in human prostate cancer by unknown mechanisms. We found that CYP24A1 expression is inversely correlated with promoter DNA methylation in prostate cancer cell lines. Treatment with the DNA methyltransferase inhibitor 5-aza-2′- deoxycytidine (DAC) activates CYP24A1 expression in prostate cancer cells. In vitro methylation of the CYP24A1 promoter represses its promoter activity. Furthermore, inhibition of histone deacetylases by trichostatin A (TSA) enhances the expression of CYP24A1 in prostate cancer cells. Quantitative chromatin immunoprecipitation-PCR (ChIP-qPCR) reveals that specific histone modifications are associated with the CYP24A1 promoter region. Treatment with TSA increases H3K9ac and H3K4me2 and simultaneously decreases H3K9me2 at the CYP24A1 promoter. ChIP-qPCR assay reveals that treatment with DAC and TSA increases the recruitment of vitamin D receptor to the CYP24A1 promoter. Reverse transcriptase-PCR analysis of paired human prostate samples revealed that CYP24A1 expression is downregulated in prostate malignant lesions compared with adjacent histologically benign lesions. Bisulfite pyrosequencing shows that CYP24A1 gene is hypermethylated in malignant lesions compared with matched benign lesions. Our findings indicate that repression of CYP24A1 gene expression in human prostate cancer cells is mediated in part by promoter DNA methylation and repressive histone modifications.

Original languageEnglish (US)
Pages (from-to)5953-5962
Number of pages10
JournalCancer Research
Volume70
Issue number14
DOIs
StatePublished - Jul 15 2010

Fingerprint

Epigenomics
Prostatic Neoplasms
trichostatin A
Histone Code
decitabine
DNA Methylation
Prostate
Vitamin D3 24-Hydroxylase
Down-Regulation
Calcitriol Receptors
Histone Deacetylases
Calcitriol
Chromatin Immunoprecipitation
Methyltransferases
Reverse Transcriptase Polymerase Chain Reaction
Genetic Promoter Regions
Methylation
Genes
Homeostasis
Calcium

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Luo, W., Karpf, A. R., Deeb, K. K., Muindi, J. R., Morrison, C. D., Johnson, C. S., & Trump, D. L. (2010). Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Research, 70(14), 5953-5962. https://doi.org/10.1158/0008-5472.CAN-10-0617

Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. / Luo, Wei; Karpf, Adam R.; Deeb, Kristin K.; Muindi, Josephia R.; Morrison, Carl D.; Johnson, Candace S.; Trump, Donald L.

In: Cancer Research, Vol. 70, No. 14, 15.07.2010, p. 5953-5962.

Research output: Contribution to journalArticle

Luo, W, Karpf, AR, Deeb, KK, Muindi, JR, Morrison, CD, Johnson, CS & Trump, DL 2010, 'Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer', Cancer Research, vol. 70, no. 14, pp. 5953-5962. https://doi.org/10.1158/0008-5472.CAN-10-0617
Luo, Wei ; Karpf, Adam R. ; Deeb, Kristin K. ; Muindi, Josephia R. ; Morrison, Carl D. ; Johnson, Candace S. ; Trump, Donald L. / Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. In: Cancer Research. 2010 ; Vol. 70, No. 14. pp. 5953-5962.
@article{40e2cce5716b495cba65a20e506eb807,
title = "Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer",
abstract = "Calcitriol, a regulator of calcium homeostasis with antitumor properties, is degraded by the product of the CYP24A1 gene, which is downregulated in human prostate cancer by unknown mechanisms. We found that CYP24A1 expression is inversely correlated with promoter DNA methylation in prostate cancer cell lines. Treatment with the DNA methyltransferase inhibitor 5-aza-2′- deoxycytidine (DAC) activates CYP24A1 expression in prostate cancer cells. In vitro methylation of the CYP24A1 promoter represses its promoter activity. Furthermore, inhibition of histone deacetylases by trichostatin A (TSA) enhances the expression of CYP24A1 in prostate cancer cells. Quantitative chromatin immunoprecipitation-PCR (ChIP-qPCR) reveals that specific histone modifications are associated with the CYP24A1 promoter region. Treatment with TSA increases H3K9ac and H3K4me2 and simultaneously decreases H3K9me2 at the CYP24A1 promoter. ChIP-qPCR assay reveals that treatment with DAC and TSA increases the recruitment of vitamin D receptor to the CYP24A1 promoter. Reverse transcriptase-PCR analysis of paired human prostate samples revealed that CYP24A1 expression is downregulated in prostate malignant lesions compared with adjacent histologically benign lesions. Bisulfite pyrosequencing shows that CYP24A1 gene is hypermethylated in malignant lesions compared with matched benign lesions. Our findings indicate that repression of CYP24A1 gene expression in human prostate cancer cells is mediated in part by promoter DNA methylation and repressive histone modifications.",
author = "Wei Luo and Karpf, {Adam R.} and Deeb, {Kristin K.} and Muindi, {Josephia R.} and Morrison, {Carl D.} and Johnson, {Candace S.} and Trump, {Donald L.}",
year = "2010",
month = "7",
day = "15",
doi = "10.1158/0008-5472.CAN-10-0617",
language = "English (US)",
volume = "70",
pages = "5953--5962",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer

AU - Luo, Wei

AU - Karpf, Adam R.

AU - Deeb, Kristin K.

AU - Muindi, Josephia R.

AU - Morrison, Carl D.

AU - Johnson, Candace S.

AU - Trump, Donald L.

PY - 2010/7/15

Y1 - 2010/7/15

N2 - Calcitriol, a regulator of calcium homeostasis with antitumor properties, is degraded by the product of the CYP24A1 gene, which is downregulated in human prostate cancer by unknown mechanisms. We found that CYP24A1 expression is inversely correlated with promoter DNA methylation in prostate cancer cell lines. Treatment with the DNA methyltransferase inhibitor 5-aza-2′- deoxycytidine (DAC) activates CYP24A1 expression in prostate cancer cells. In vitro methylation of the CYP24A1 promoter represses its promoter activity. Furthermore, inhibition of histone deacetylases by trichostatin A (TSA) enhances the expression of CYP24A1 in prostate cancer cells. Quantitative chromatin immunoprecipitation-PCR (ChIP-qPCR) reveals that specific histone modifications are associated with the CYP24A1 promoter region. Treatment with TSA increases H3K9ac and H3K4me2 and simultaneously decreases H3K9me2 at the CYP24A1 promoter. ChIP-qPCR assay reveals that treatment with DAC and TSA increases the recruitment of vitamin D receptor to the CYP24A1 promoter. Reverse transcriptase-PCR analysis of paired human prostate samples revealed that CYP24A1 expression is downregulated in prostate malignant lesions compared with adjacent histologically benign lesions. Bisulfite pyrosequencing shows that CYP24A1 gene is hypermethylated in malignant lesions compared with matched benign lesions. Our findings indicate that repression of CYP24A1 gene expression in human prostate cancer cells is mediated in part by promoter DNA methylation and repressive histone modifications.

AB - Calcitriol, a regulator of calcium homeostasis with antitumor properties, is degraded by the product of the CYP24A1 gene, which is downregulated in human prostate cancer by unknown mechanisms. We found that CYP24A1 expression is inversely correlated with promoter DNA methylation in prostate cancer cell lines. Treatment with the DNA methyltransferase inhibitor 5-aza-2′- deoxycytidine (DAC) activates CYP24A1 expression in prostate cancer cells. In vitro methylation of the CYP24A1 promoter represses its promoter activity. Furthermore, inhibition of histone deacetylases by trichostatin A (TSA) enhances the expression of CYP24A1 in prostate cancer cells. Quantitative chromatin immunoprecipitation-PCR (ChIP-qPCR) reveals that specific histone modifications are associated with the CYP24A1 promoter region. Treatment with TSA increases H3K9ac and H3K4me2 and simultaneously decreases H3K9me2 at the CYP24A1 promoter. ChIP-qPCR assay reveals that treatment with DAC and TSA increases the recruitment of vitamin D receptor to the CYP24A1 promoter. Reverse transcriptase-PCR analysis of paired human prostate samples revealed that CYP24A1 expression is downregulated in prostate malignant lesions compared with adjacent histologically benign lesions. Bisulfite pyrosequencing shows that CYP24A1 gene is hypermethylated in malignant lesions compared with matched benign lesions. Our findings indicate that repression of CYP24A1 gene expression in human prostate cancer cells is mediated in part by promoter DNA methylation and repressive histone modifications.

UR - http://www.scopus.com/inward/record.url?scp=77955037065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955037065&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-0617

DO - 10.1158/0008-5472.CAN-10-0617

M3 - Article

C2 - 20587525

AN - SCOPUS:77955037065

VL - 70

SP - 5953

EP - 5962

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 14

ER -